{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:56:42Z","timestamp":1781204202226,"version":"3.54.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Rare pediatric vascular tumors and malformations can be diagnostically and therapeutically challenging. They may present atypically, mimic more common conditions, or be life-threatening. Understanding of the various conditions, early recognition, and multidisciplinary management are essential for successful treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective review was performed of selected pediatric vascular anomaly cases managed at a tertiary referral center between March 2023 and August 2025. Cases were chosen based on diagnostic complexity, rarity, and the requirement for multidisciplinary and\/or targeted systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation Summary:<\/jats:title>\n                    <jats:p>Five cases are presented: kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon, congenital hemangioma, generalized lymphatic anomaly, and PIK3CA-related overgrowth spectrum disorder presenting with multifocal osteolytic lesions and fractures. Diagnoses were established through radiologic, histopathologic, and targeted genetic and molecular testing. Management combined wound care and reconstruction with systemic therapies. Propranolol was used as first-line therapy in infantile hemangioma, corticosteroids and sirolimus were used in vascular tumors with hematological complications, and alpelisib was utilized in PIK3CA-related disease. Outcomes were variable but demonstrated significant symptomatic and functional improvement with good overall tolerance of systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These cases highlight the heterogeneity of pediatric vascular anomalies and their potential to mimic nonvascular pathology. Hand and plastic surgeons play a key role in recognition, biopsy, wound care and reconstruction, and rehabilitation within multidisciplinary teams. Novel targeted systemic therapies, such as sirolimus and alpelisib, alongside more traditional agents, including propranolol and corticosteroids, are central where surgery alone is inadequate. Awareness of these rare vascular anomalies is essential for timely diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sap.0000000000004755","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:02:43Z","timestamp":1776873763000},"page":"73-81","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Unusual Vascular Anomalies in Plastic Surgery"],"prefix":"10.1097","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-7765","authenticated-orcid":false,"given":"Sanjeev Chaand","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Vidyadharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"R1-20260611","doi-asserted-by":"crossref","first-page":"e220328","DOI":"10.1148\/ryct.220328","article-title":"Vascular malformations and tumors: a review of classification and imaging features for cardiothoracic radiologists","volume":"5","author":"Ota","year":"2023","journal-title":"Radiol Cardiothorac Imaging"},{"key":"R2-20260611","doi-asserted-by":"crossref","first-page":"e172836","DOI":"10.1172\/JCI172836","article-title":"Infantile hemangioma: the common and enigmatic vascular tumor","volume":"134","author":"Holm","year":"2024","journal-title":"J Clin Invest"},{"key":"R3-20260611","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0034-1376264","article-title":"Medical therapy for pediatric vascular anomalies","volume":"28","author":"Margolin","year":"2014","journal-title":"Semin Plast Surg"},{"key":"R4-20260611","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0037-1604297","article-title":"Advances in the medical management of vascular anomalies","volume":"34","author":"Ricci","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"R5-20260611","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Leaute-Labreze","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-20260611","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"Leaute-Labreze","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20260611","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pbc.24103","article-title":"Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon","volume":"59","author":"Chiu","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20260611","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/jiaps.jiaps_117_22","article-title":"Propranolol for vascular anomalies: efficacy and complications in pediatric patients","volume":"28","author":"Gupta","year":"2023","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"R9-20260611","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0037-1604296","article-title":"Vascular anomalies caused by abnormal signaling within endothelial cells: targets for novel therapies","volume":"34","author":"Nguyen","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"R10-20260611","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","article-title":"Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review","volume":"71","author":"Freixo","year":"2020","journal-title":"J Vasc Surg"},{"key":"R11-20260611","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/hematology.2024000599","article-title":"Targeted medical therapies for vascular anomalies","volume":"2024","author":"Borst","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R12-20260611","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjd.16601","article-title":"Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon","volume":"179","author":"Ji","year":"2018","journal-title":"Br J Dermatol"},{"key":"R13-20260611","doi-asserted-by":"crossref","first-page":"161932","DOI":"10.1016\/j.jpedsurg.2024.161932","article-title":"Analysis of risk factors for Kasabach-Merritt phenomenon in children with kaposiform hemangioendothelioma","volume":"60","author":"Chen","year":"2025","journal-title":"J Pediatr Surg"},{"key":"R14-20260611","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ijc.34509","article-title":"Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: continuing successes and ongoing challenges","volume":"153","author":"Zhou","year":"2023","journal-title":"Int J Cancer"},{"key":"R15-20260611","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1055\/s-0040-1718901","article-title":"Sirolimus for kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in a neonate","volume":"10","author":"Cabrera","year":"2020","journal-title":"AJP Rep"},{"key":"R16-20260611","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/17531934241310725","article-title":"Intrinsic neonatal limb ischaemia: a systematic review","volume":"50","author":"Singal","year":"2025","journal-title":"J Hand Surg Eur Vol"},{"key":"R17-20260611","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/idoj.idoj_274_21","article-title":"Pyoderma gangrenosum with splenic abscess: a rare association","volume":"13","author":"Bansal","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"R18-20260611","doi-asserted-by":"crossref","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"R19-20260611","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20260611","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2021014027","article-title":"Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial","volume":"139","author":"Ji","year":"2022","journal-title":"Blood"},{"key":"R21-20260611","doi-asserted-by":"crossref","first-page":"e000816","DOI":"10.1136\/bmjpo-2020-000816","article-title":"Congenital haemangiomas: a single-centre retrospective review","volume":"4","author":"Braun","year":"2020","journal-title":"BMJ Paediatr Open"},{"key":"R22-20260611","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jpeds.2012.02.052","article-title":"A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature","volume":"161","author":"Kanada","year":"2012","journal-title":"J Pediatr"},{"key":"R23-20260611","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/pbc.25914","article-title":"Clinical features and prognosis of generalized lymphatic anomaly, kaposiform lymphangiomatosis, and Gorham-Stout disease","volume":"63","author":"Ozeki","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20260611","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jvsv.2021.03.001","article-title":"A narrative review of the role of sirolimus in the treatment of congenital vascular malformations","volume":"9","author":"Geeurickx","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"R25-20260611","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000530897","article-title":"Generalized lymphatic anomaly as a differential diagnosis of lytic lesions","volume":"16","author":"Catani","year":"2023","journal-title":"Case Rep Oncol"},{"key":"R26-20260611","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.3390\/ijms26136126","article-title":"Targeted therapy for complex lymphatic anomalies in patients with Noonan syndrome and related disorders","volume":"26","author":"Leenders","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R27-20260611","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1097\/MPH.0000000000000436","article-title":"Personalized therapy for generalized lymphatic anomaly\/Gorham-Stout disease with a combination of sunitinib and Taxol","volume":"37","author":"Rossler","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"R28-20260611","doi-asserted-by":"crossref","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet Med"},{"key":"R29-20260611","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/lrb.2017.0062","article-title":"Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review","volume":"16","author":"Wiegand","year":"2018","journal-title":"Lymphat Res Biol"}],"container-title":["Annals of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:00:31Z","timestamp":1781200831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004755"}},"subtitle":["A Case Series"],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/sap.0000000000004755","relation":{},"ISSN":["0148-7043","1536-3708"],"issn-type":[{"value":"0148-7043","type":"print"},{"value":"1536-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"2025-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}